OFFER DEADLINE01/07/2020 15:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions
ORGANISATION/COMPANYInternational Research Projects Office
DEPARTMENTPromotion and Advisory Unit
Professor Fermín Sánchez de Medina, from the Department of Pharmacology at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Individual Fellowships (MSCA-IF) in 2020 at this University. Please note that applicants must comply with the Mobility Rule (more information: http://sl.ugr.es/0aNV).
Brief description of the institution:
The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. The UGR has been awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The UGR is also a leading institution in research, located in the top 5/10 of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding.
UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking (http://sl.ugr.es/0aw0). The Academic Ranking of World Universities (ARWU) places the UGR in 268th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research. From the perspective of specialist areas in the ARWU rankings, the UGR is outstanding in Documentation (ranked in the 36th in the world) or Food science technology (ranked 37th in the world), Mathematics and Computer Science (ranked among the top 76-100 in the world).
The UGR has 4 researchers at the top of the Highly Cited Researchers (HCR) list in the Computer Science area. With regard to broader subject fields, the UGR is ranked in 45th position in the universities worldwide in the discipline of Engineering. It is also well recognized for its web presence (http://sl.ugr.es/0a6i) taking 36th place in the top 200 Universities in Europe. Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 66 projects, with total funding of 18.02 million euros, and for H2020, 80 projects with total funding around 20.6 million euros.
Brief description of the Centre/Research Group
Our research group works in the field of pathophysiology (ion transport, alkaline phosphatase, inflammatory markers) and pharmacology (flavonoids, glycomacropeptide, oligosaccharides, bisphosphonates, corticosteroids) of inflammatory bowel disease and obesity/metabolic syndrome. Central to both is an alteration of the function of intestinal barrier, a fundamental element of intestinal homeostasis involved in inflammatory processes such as inflammatory bowel disease, but also many other intestinal and systemic diseases, including metabolic syndrome, acute pancreatitis, liver disease, sepsis, etc.
We use various cellular models, including intestinal organoids, and animal models, such as KO mice for the intestinal epithelial glucocorticoid receptor Nr3c1 (developed by our group), haplodeficient mice for tissue nonspecific alkaline phosphatase (Alpl), immunodeficient mice Zucker rats, etc. The experimental techniques used include molecular techniques, FACS, immunohistochemistry, gene silencing, studies of electrolytic transport, metagenomics of fecal microbiota, pharmacogenomics, etc.
We have received about 650,000 € in the last 5 years, coming mainly from competitive public projects but also from contracts with companies and projects financed by foundations. Our group is a member of the Center for Biomedical Research in the Liver and Digestive Diseases Network (CIBERehd), which brings together the most prestigious groups active in the research of gastroenterology in Spain. Our publications profile is available at https://scholar.google.es/citations?user=Y0GzurEAAAAJ&hl=en
Glucocorticoids (GC) are widely used to control sepsis, in addition to being part of the physiological response. Available evidence indicates that endogenous GC are insufficiente to support blood pressure and limit the initial inflammatory response, while exogenous GC exhibit a significant albeit variable effect, and their efficacy appears to be globally inferior to that in other inflammatory conditions. This project will explore the hypothesis that the therapeutic benefit of GC in sepsis is limited in part by their delterious actions on intestinal barrier function. Our research group has established that GC weaken the capacity of the intestine to contain components of the intestinal microbiota in experimental colitis, due to a great extent to their actions at the epithelial level. To this end we have developed cell specific inducible KO mice for the Gc receptor NR3C1 (Nr3c1IEC-/- mice). Since the intestinal microbiota is considered a significant source of infection/translocation in sepsis and the gut is involved in the systemic inflammatory response, this mouse model will be useful to assess the possible implication of the epithelial GC receptor in sepsis. The ultimate goal is to improve sepsis management with this type of drugs, for instance by developing GC with reduced epithelial effects.
Life Sciences (LIFE)
For a correct evaluation of your candidature, please send the documents below to Professor Fermín Sánchez de Medina (firstname.lastname@example.org):
- Letter of recommendation (optional)
The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.